The AI in cancer diagnostics market is poised for significant growth, driven by advancements in technology and increasing demand for early detection solutions.
According to recent projections, the market is expected to increase from $0.79 billion in 2025 to $0.96 billion in 2026, achieving a compound annual growth rate (CAGR) of 20.2%. This growth is attributed to the rising incidence of cancer globally, with the National Cancer Institute forecasting 2 million new cases in the U.S. by 2024 and 29.9 million worldwide by 2040. The integration of AI-powered imaging systems and deep learning technologies is enhancing diagnostic accuracy and efficiency, positioning AI as a key player in personalized treatment approaches.
Notably, the market is also witnessing strategic collaborations, such as Lunit's acquisition of Volpara, which aims to strengthen AI-driven cancer diagnosis capabilities in the U.S. This trend reflects a broader movement within the industry, where partnerships between AI developers and healthcare institutions are fostering the creation of innovative diagnostic tools.
Looking ahead, the market is projected to reach $1.97 billion by 2030, with a CAGR of 19.9%. The ongoing advancements in predictive analytics and digital health technologies are likely to further propel this growth. As the landscape evolves, stakeholders in healthcare and technology must adapt to these changes to enhance their market presence and improve patient outcomes through more accurate and accessible diagnostic solutions.